A Comparative Study to Evaluate the Pharmacotherapy of Type II Diabetes in Patients Visiting Tertiary Care Teaching Hospital and Private Clinic

Introduction: Diabetes mellitus (DM) refers to a bunch of disorders of metabolism that share the phenotypic sign of hyperglycemia. Different variants of DM are caused due to the interaction of various genetic factors with environmental factors. Materials and Methods: This is prospective, comparative, and observational study. The study was conducted at SMBT Medical Institute and Research Centre Dhamangaon Nashik and private Diabetic clinic. Each center was 50 purposive sampling. Inclusion Criteria: All those patients who are diagnosed with Type II Diabetes and age of 18 years and above belonging to either gender were included in the study. Exclusion Criteria: Patients who are not willing to sign the informed consent were excluded from the study. Those individuals who are having Type I diabetes and suffering from co-morbid conditions such as hypertension, hyperthyroidism, and immune deficiency syndrome were excluded. Results: In our study, results revealed that mono and combination therapies for the treatment of type II DM. The present study revealed that most of the physicians initially prescribed mono therapy (25%) includes Metformin/Glibenclamide/Glimepiride/Gliclazide to control hyperglycemia followed by dual therapy (35%) FDC of Metformin + Pioglitazone/Metformin + Glipizide/Metformin + Glimepiride/Metformin + Saxagliptin/Metformin + Voglibose and triple therapy (40%) includes Metformin + Glimepiride + Pioglitazone in group A. In Group B, mono therapy (35%) and triple therapy (35%) were used more commonly over dual therapy (30%) to control hyperglycemic. Conclusion: Hence, while comparing between tertiary care versus private care hospital, Group A: Biguanide: Metformin and Sulfonylureas: Glibenclamide, Glipizide, Gliclazide, and Glimepiride was most commonly prescribed drug. In Group B: Dapagliflozin (Sodium-glucose co-transport-2 inhibitors) and Teneligliptin: Dipeptidyl peptidase-4 inhibitors were most commonly used in private hospital